All accepted abstracts are available in the Journal for ImmunoTherapy of Cancer (JITC).

Abstract Titles

Poster Presentation Dates

All odd numbered posters will be presented on Wednesday, Nov. 11, from 5:15-5:45 p.m. EST and Friday, Nov. 13, from 4:40-5:10 p.m. EST. Even numbered posters will be presented on Thursday, Nov. 12, from 4:50-5:20 p.m. EST and Saturday, Nov. 14, from 1-1:30 p.m. EST.

Posters will be on display from 8 a.m. on Monday, Nov. 9, until the virtual poster hall closes on December 31, 2020.

#	Type	Title	Authors	Category	Keywords
311	Poster Presentation	Phase II Trial of Lymphodepletion Plus Adoptive Cell Transfer with or Without Dendritic Cell Vaccination in Patients with Metastatic Melanoma	Chantal Saberian, MD; Rodabe N. Amaria, MD; Cara Haymaker, PhD; Marie Andree Forget, PhD; Roland L. Bassett, BS; Isabella C. Glitza, MD, PhD; Gregory A. Lizee, PhD; Cassian Yee, MD; Jeniffer L. McQuade, MD; Michael K. Wong, MD PhD FRCPC; Hussein A. Tawbi, MD, PhD; Sapna Patel, MD; Adi Diab, MD; Michael A. Davies, MD, PhD; Patrick M. Hwu, MD; Chantale Bernatchez, PhD;	Completed Clinical Trials	Antigen presenting cells; Clinical study; Clinical trial; Dendritic cell; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Vaccine
368	Oral Presentation	REVEAL: Phase 1 dose-escalation study of NKTR-262, a novel TLR7/8 agonist, plus bempegaldesleukin: local innate immune activation and systemic adaptive immune expansion for treating solid tumors	Adi Diab, MD; Brendan D. Curti, MD; Mehmet A. Bilen, MD; Andrew S. Brohl, MD; Evidio Domingo-Musibay, MD; Erkut H. Borazanci, MD; Christie Fanton, PhD; Cat Haglund; Mona Vimal, MSc; Mann Muhsin, MD; Mario Q. Marcondes, MD, PhD; Anh Nguyen; Mary A. Tagliaferri, MD; Wei Lin, MD; Jonathan Zalevsky, PhD; Sandra P. D'Angelo, MD;	In-Progress Clinical Trials	Biomarkers; Clinical trial; Cytokine; Solid tumors; T cell; TLR; Tumor microenvironment
397	Poster Presentation	Intra-Tumor Immunotherapy Injections utilizing Image guidance in Interventional Radiology: Clinical Trial Experience at a Tertiary care Cancer Center	Ravi Murthy; Rahul A. Sheth, MD; Alda Tam; Sanjay Gupta; Vivek Subbiah, MD; Filip Janku, MD, PhD; Timothy A. Yap, MD, PhD; Adi Diab, MD; Aung Naing, MD, FACP; Sapna Patel, MD; Funda Meric-Bernstam, MD;	In-Progress Clinical Trials	Clinical trial; Solid tumors; Vaccine
420	Oral Presentation	Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study	Adi Diab, MD; Scott S. Tykodi, MD, PhD; Gregory A. Daniels, MD, PhD; Michele Maio, MD; Brendan D. Curti, MD; Karl D. Lewis, MD; Sekwon Jang, MD; Ewa Kalinka, PhD, MD; Igor Puzanov, MD, MSCI; Alexander I. Spira, MD, PhD, FACP; Daniel C. Cho, MD; Shanhong Guan, PhD; Erika Puente, MD; Ute Hoch, PhD; Sue L. Currie, PhD; Tuan Nguyen, PhD; Wei Lin, MD; Mary A. Tagliaferri, MD; Jonathan Zalevsky, PhD; Mario Sznol, MD; Michael E. Hurwitz, MD, PhD;	In-Progress Clinical Trials	Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Cytokine; Solid tumors; T cell
638	Poster Presentation	Plasma Proteome Analysis in Patients with Immune Checkpoint Inhibitors Related Arthritis and Pneumonitis	Noha Abdel-Wahab, MD, PhD; Adi Diab, MD; Hiroyuki Katayama, PhD; Sang Kim, MD, PhD; Samir M. Hanash, MD, PhD; Maria Suarez-Almazor, MD, PhD;	Immunotherapy Toxicities	Checkpoint blockade; Immune toxicity; Proteomics
657	Poster Presentation	Interleukin-6 Receptor Blockade for Management of Immune Checkpoint Inhibitor Related Adverse Events in Patients with Melanoma	Chantal Saberian, MD; Faisal Fa'ak; Jean H. Tayar, MD; Maryam Buni, MD; Sang Kim, MD, PhD; Huifang Lu, MD, PhD; Maria Suarez-Almazor, MD, PhD; Stephen Gruschkus, PhD; May Daher, MD; Kaysia Ludford; Daniel Johnson, MD; Noha Abdel-Wahab, MD, PhD; Adi Diab, MD;	Immunotherapy Toxicities	Autoimmunity; Cytokine; Immune toxicity; Inflammation
658	Poster Presentation	Toxicities of single agent and combination immune checkpoint inhibitors in patients with pre-existing autoimmune diseases.	Sabina Sandigursky; Safa Houssein; Xerxes Pundole, MD, PhD; Elizaveta Efuni; Samuel Cytryn; Maryam Buni, MD; Anna C. Pavlick, MD, MBA; Michelle Krogsgaard, PhD; Chantal Saberian, MD; Mehmet Altan, MD; Maria Suarez-Almazor, MD, PhD; Jeffrey S. Weber, MD, PhD; Adi Diab, MD; Noha Abdel-Wahab, MD, PhD;	Immunotherapy Toxicities	Autoimmunity; Checkpoint blockade; Immune toxicity
856	Poster Presentation	Preliminary review of Diabetes Mellitus incidence in patients treated with immune checkpoint inhibitors (ICI) therapy – Roswell Park Comprehensive Cancer Center (RPCCC) experience	Zhen Zhang, PharmD, BCPS; Grazyna Riebandt, PharmD, BCOP; Rajeev Sharma, MD, FACE; Jordan Scott, BS; Lamya Hamad, RPh, MPH; Laurie Plewinski, BS;	Immunotherapy Toxicities	Antibody; Autoimmunity; Checkpoint blockade; Immune toxicity; Solid tumors